Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: burke j. Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358. Nature. 2011. PMID: 21886163 Clinical Trial.
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. Small EJ, et al. Among authors: burke jm. Mol Ther. 2006 Jul;14(1):107-17. doi: 10.1016/j.ymthe.2006.02.011. Epub 2006 May 9. Mol Ther. 2006. PMID: 16690359 Free article. Clinical Trial.
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.
Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH. Hwang TH, et al. Among authors: burke j. Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19. Mol Ther. 2011. PMID: 21772252 Free PMC article. Clinical Trial.
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH. Breitbach CJ, et al. Among authors: burke j. Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7. Cancer Res. 2013. PMID: 23393196 Clinical Trial.
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Heo J, et al. Among authors: burke j. Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10. Nat Med. 2013. PMID: 23396206 Free PMC article. Clinical Trial.
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ. Cripe TP, et al. Among authors: burke jm. Mol Ther. 2015 Mar;23(3):602-8. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22. Mol Ther. 2015. PMID: 25531693 Free PMC article. Clinical Trial.
Oncolytic viruses: perspectives on clinical development.
Burke J, Nieva J, Borad MJ, Breitbach CJ. Burke J, et al. Curr Opin Virol. 2015 Aug;13:55-60. doi: 10.1016/j.coviro.2015.03.020. Epub 2015 May 16. Curr Opin Virol. 2015. PMID: 25989094 Review.
4,202 results